AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma

Smita Mishra, Heather Cartwright
{"title":"AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma","authors":"Smita Mishra, Heather Cartwright","doi":"10.3833/PDR.V2015I5.2102","DOIUrl":null,"url":null,"abstract":"With a pair of deals worth more than US$1.7 B, AstraZeneca has taken steps to strengthen and expand its immuno-oncology portfolio, partnering with Innate Pharma for the co-development and commercialisation of the Phase II anti-NKG2A antibody IPH2201 and out-licensing its immune checkpoint inhibitor MEDI4736 (durvalumab) to Celgene for development in haematological malignancies. AstraZeneca also plans to test the two assets in combination in solid tumours, adding to the company’s broad programme of combination trials in immuno-oncology.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2015I5.2102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

With a pair of deals worth more than US$1.7 B, AstraZeneca has taken steps to strengthen and expand its immuno-oncology portfolio, partnering with Innate Pharma for the co-development and commercialisation of the Phase II anti-NKG2A antibody IPH2201 and out-licensing its immune checkpoint inhibitor MEDI4736 (durvalumab) to Celgene for development in haematological malignancies. AstraZeneca also plans to test the two assets in combination in solid tumours, adding to the company’s broad programme of combination trials in immuno-oncology.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿斯利康通过与Celgene和Innate Pharma的交易加强了免疫肿瘤产品组合
随着两笔价值超过17亿美元的交易,阿斯利康已采取措施加强和扩大其免疫肿瘤学产品组合,与Innate Pharma合作共同开发和商业化II期抗nkg2a抗体IPH2201,并将其免疫检查点抑制剂MEDI4736 (durvalumab)授权给Celgene用于血液系统恶性肿瘤的开发。阿斯利康还计划在实体肿瘤中对这两种资产进行联合试验,从而为该公司在免疫肿瘤学领域的广泛联合试验计划增加新的内容。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
IMS PharmaDeals Review of 2014 Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9 AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1